Moderna (MRNA) Stock Price, News & Analysis

Company Overview

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

Written by Jeffrey Neal Johnson

Key Stats

• Today's Range: $35.05 to $36.75
• 50-Day Range: $30.53 to $47.53
• 52-Week Range: $29.25 to $170.47
• Volume: 10.03 million shs
• Average Volume: 12.96 million shs
• Market Capitalization: $13.82 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.63
• Consensus Rating: Hold

Moderna Stock Analysis - MarketRank™

Moderna scored higher than 96% of companies evaluated by MarketBeat, and ranked 49th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Moderna has received a consensus rating of Hold. The company's average rating score is 2.04, and is based on 3 buy ratings, 15 hold ratings, and 4 sell ratings.

Amount of Analyst Coverage

Moderna has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Moderna are expected to grow in the coming year, from ($8.72) to ($6.29) per share.

Price to Book Value per Share Ratio

Moderna has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.84% of the float of Moderna has been sold short.

Short Interest Ratio / Days to Cover

Moderna has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moderna has recently decreased by 5.60%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moderna does not currently pay a dividend.

Dividend Growth

Moderna does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -2.71

Percentage of Shares Shorted

11.84% of the float of Moderna has been sold short.

Short Interest Ratio / Days to Cover

Moderna has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moderna has recently decreased by 5.60%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.19

News Sentiment

Moderna has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 53 news articles for Moderna this week, compared to 24 articles on an average week.

Search Interest

Only 71 people have searched for MRNA on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.

MarketBeat Follows

40 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $115,210.00 in company stock.

Percentage Held by Insiders

15.70% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRNA Stock Analysis - Frequently Asked Questions

How have MRNA shares performed this year?

Moderna's stock was trading at $41.58 at the start of the year. Since then, MRNA stock has decreased by 13.7% and is now trading at $35.90.
View the best growth stocks for 2025 here.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) posted its quarterly earnings data on Thursday, November, 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business's revenue was up 3.8% compared to the same quarter last year.

When did Moderna IPO?

Moderna (MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Top institutional investors of Moderna include Vanguard Group Inc. (10.48%), Baillie Gifford & Co. (10.11%), FMR LLC (4.85%) and Theleme Partners LLP (1.90%). Insiders that own company stock include Stephane Bancel, Noubar Afeyan, Stephen Hoge, Shannon Thyme Klinger, Juan Andres, James M Mock, Arpa Garay and David W Meline.
View institutional ownership trends.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/19/2025
• Next Earnings (Estimated): 4/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRNA
• CUSIP: N/A
• CIK: 1682852
• Web: www.modernatx.com
• Phone: (617) 714-6500
• Fax: N/A
• Employees: 5,600
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $60.63
• High Stock Price Target: $179.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +68.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.04
• Research Coverage: 23 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($9.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,561,000,000.00
• Net Margins: -110.04%
• Pretax Margin: -111.46%
• Return on Equity: -28.74%
• Return on Assets: -21.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.67
• Quick Ratio: 3.62

Sales & Book Value

• Annual Sales: $3.24 billion
• Price / Sales: 4.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $28.33 per share
• Price / Book: 1.27

Miscellaneous

• Outstanding Shares: 384,820,000
• Free Float: 326,326,000
• Market Cap: $13.82 billion
• Optionable: Optionable
• Beta: 1.59